Earlier this month, Amicus Therapeutics opened its new $25 million Global Research and Gene Therapy Center in West Philadelphia’s uCity Square neighborhood.
The new 75,000-square-foot facility occupies the top three floors of 3675 Market Street and features an open-space design with state-of-the-art labs and offices.
“Philadelphia is a magnet for talent in gene therapy and an engine for innovation,” said John F. Crowley, Chairman and CEO of Amicus. “This new global research center located in the ‘cradle of liberty’ will become part of the ‘cradle of cures’ as we move many gene therapy programs forward toward patients in need.”
In the next few years, Amicus expects to grow its staff to over 200 researchers.
Amicus partnered with the University of Pennsylvania in 2019 to gain exclusive global rights to develop possible treatments for 50 rare diseases in collaboration with Penn’s Next Generation Gene Therapy Technologies from the Wilson Lab. This partnership with Penn combined with its expansion in uCity Square allows Amicus to grow its research capabilities.
Amicus continues to focus on discovering, developing, and delivering medicines for people living with rare metabolic diseases. During 2019 BIO, Amicus’ President and COO, Bradley Campbell, said the company chose to operate in Philadelphia because of the innovation, entrepreneurship, and universities here.